Parray Aijaz, Siddique Hifzur R, Kuriger Jacquelyn K, Mishra Shrawan K, Rhim Johng S, Nelson Heather H, Aburatani Hiroyuki, Konety Badrinath R, Koochekpour Shahriar, Saleem Mohammad
Section of Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, MN.
Int J Cancer. 2014 Dec 1;135(11):2493-506. doi: 10.1002/ijc.28919. Epub 2014 Apr 29.
High-risk populations exhibit early transformation of localized prostate cancer (CaP) disease to metastasis which results in the mortality of such patients. The paucity of knowledge about the molecular mechanism involved in acquiring of metastatic behavior by primary tumor cells and non-availability of reliable phenotype-discriminating biomarkers are stumbling blocks in the management of CaP disease. Here, we determine the role and translational relevance of ROBO1 (an organogenesis-associated gene) in human CaP. Employing CaP-progression models and prostatic tissues of Caucasian and African-American patients, we show that ROBO1 expression is localized to cell-membrane and significantly lost in primary and metastatic tumors. While Caucasians exhibited similar ROBO1 levels in primary and metastatic phenotype, a significant difference was observed between tumor phenotypes in African-Americans. Epigenetic assays identified promoter methylation of ROBO1 specific to African-American metastatic CaP cells. Using African-American CaP models for further studies, we show that ROBO1 negatively regulates motility and invasiveness of primary CaP cells, and its loss causes these cells to acquire invasive trait. To understand the underlying mechanism, we employed ROBO1-expressing/ROBO1-C2C3-mutant constructs, immunoprecipitation, confocal-microscopy and luciferase-reporter techniques. We show that ROBO1 through its interaction with DOCK1 (at SH3-SH2-domain) controls the Rac-activation. However, loss of ROBO1 results in Rac1-activation which in turn causes E-Cadherin/β-catenin cytoskeleton destabilization and induction of cell migration. We suggest that ROBO1 is a predictive biomarker that has potential to discriminate among CaP types, and could be exploited as a molecular target to inhibit the progression of disease as well as treat metastasis in high-risk populations such as African-Americans.
高危人群中,局部前列腺癌(CaP)疾病会早期转变为转移,导致此类患者死亡。对原发性肿瘤细胞获得转移行为所涉及的分子机制了解不足,以及缺乏可靠的表型区分生物标志物,是CaP疾病管理中的绊脚石。在此,我们确定了ROBO1(一种与器官发生相关的基因)在人类CaP中的作用及转化相关性。利用CaP进展模型以及白种人和非裔美国患者的前列腺组织,我们发现ROBO1表达定位于细胞膜,在原发性和转移性肿瘤中显著缺失。虽然白种人在原发性和转移表型中ROBO1水平相似,但在非裔美国人的肿瘤表型之间观察到显著差异。表观遗传学分析确定了非裔美国转移性CaP细胞特有的ROBO基因启动子甲基化。使用非裔美国CaP模型进行进一步研究,我们发现ROBO1负向调节原发性CaP细胞的运动性和侵袭性,其缺失会使这些细胞获得侵袭性特征。为了解潜在机制,我们采用了表达ROBO1/ROBO1 - C2C3突变体构建体、免疫沉淀、共聚焦显微镜和荧光素酶报告技术。我们发现ROBO1通过与DOCK1(在SH3 - SH2结构域)相互作用控制Rac激活。然而,ROBO1的缺失导致Rac1激活,进而导致E - 钙黏蛋白/β - 连环蛋白细胞骨架不稳定并诱导细胞迁移。我们认为ROBO1是一种有潜力区分不同类型CaP的预测性生物标志物,并且可被用作分子靶点来抑制疾病进展以及治疗高危人群(如非裔美国人)的转移。